Aion Therapeutic Announces Closing of Second Tranche of Non-Brokered Private Placement Offering of Units
Aion Therapeutic Announces Closing of Second Tranche of Non-Brokered Private Placement Offering of Units
Toronto, Ontario--(Newsfile Corp. - October 5, 2023) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is pleased to announce that further to its press released dated September 8, 2023, it has closed the second tranche of its previously-announced non-brokered private placement (the "Unit Offering") issuing 21,500,000 units ("Units"), at a price of $0.01 per Unit, for gross proceeds of $215,000. Including the first tranche of the Unit Offering, the Company has issued a total of 64,250,000 Units for total gross proceeds of $642,500.
安大略省多倫多-(Newsfile Corp.-2023年10月5日)-Aion治療公司(CSE：AION)(“Aion治療“或”公司)欣然宣佈，繼其於2023年9月8日發佈的新聞稿後，已完成先前宣佈的第二批非經紀私募(The提供單位產品“)發行21,500,000件(”單位“)，每單位價格為0.01美元，總收益為215,000美元。包括第一批單位發行，公司共發行64,250,000個單位，總收益為642,500美元。
Each Unit consists of one common share ("Share") and one half of one common share purchase warrant ("Warrant"). Each full Warrant is exercisable to acquire one Share ("Warrant Share") for a period of eighteen months following the closing of the Unit Offering at an exercise price of $0.10 per Warrant Share.
每個單位由一個公共共享組成(“分享“)和一份普通股認購權證的一半(”搜查令“)。每份全數認股權證可行使以取得一股(”認股權證股份“)於單位發售結束後十八個月內，行使價格為每股認股權證股份0.10美元。
The Company intends to use the proceeds of the Unit Offering for general working capital purposes. All securities issued in connection with the Unit Offering are subject to a four month and one day hold as required under applicable securities laws.
本公司擬將單位發售所得款項用作一般營運資金用途。根據適用證券法的要求，所有與該單位發售有關的證券均須持有四個月零一天。
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) except pursuant to an available exemption under the 1933 Act and compliance with, or exemption from, applicable U.S. state securities laws.
本新聞稿不構成出售要約或邀請購買要約，也不會在任何司法管轄區出售任何此類要約、招攬或出售將是非法的證券。這些證券沒有，也不會根據修訂後的《1933年美國證券法》(該法案)註冊。1933年法案“)或任何州證券法，不得在美國境內或為美國人的賬戶或利益(如1933年法案下的S法規所界定)提供或銷售，除非符合1933年法案下的可用豁免，並遵守或豁免適用的美國州證券法。
About Aion Therapeutic Inc.
Aion治療公司簡介
Aion Therapeutic is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.
Aion治療是健康和健康部門內的一傢俱有前瞻性的企業，擁有多樣化的知識產權組合。憑藉對創新和變革性解決方案的承諾，該公司準備推動積極的變革，重新定義健康和健康的界限。
For further information, please contact:
如需更多資訊，請聯繫：
Aion Therapeutic Inc.
Graham Simmonds
Executive Vice Chair & CEO
(416) 843-2881
Aion治療公司
格雷厄姆·西蒙茲
執行副主席兼首席執行官
(416)843-2881
DISCLAIMER & READER ADVISORY
免責聲明和讀者建議
This release contains forward-looking information within the meaning of applicable Canadian securities legislation. Expressions such as "anticipates", "expects", "believes", "estimates", "could", "intends", "may", "plans", "predicts", "projects", "will", "would" and other similar expressions, or the negative of these terms, are generally indicative of forward-looking information. Forward-looking statements in this press release include statements regarding the use of proceeds from the Unit Offering. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information.
本新聞稿包含適用於加拿大證券法的前瞻性資訊。諸如“預期”、“預期”、“相信”、“估計”、“可能”、“打算”、“可能”、“計劃”、“預測”、“專案”、“將”、“將”和其他類似的表述，或這些術語的否定，通常表示前瞻性資訊。本新聞稿中的前瞻性陳述包括有關單位發售所得資金使用的陳述。前瞻性資訊涉及已知和未知的風險、不確定性和其他因素，可能導致實際結果或事件與此類前瞻性資訊明示或暗示的結果或事件大不相同。
In addition, the forward-looking information contained in this release is based upon what management believes to be reasonable assumptions. Readers are cautioned not to place undue reliance on forward-looking information as it is inherently uncertain, and no assurance can be given that the expectations reflected in such information will prove to be correct. The forward-looking information in this release is made as of the date hereof and, except as required under applicable securities legislation, the Company assumes no obligation to update or revise such information to reflect new events or circumstances.
此外，本新聞稿中包含的前瞻性資訊是基於管理層認為合理的假設。告誡讀者不要過度依賴前瞻性資訊，因為這些資訊本身是不確定的，不能保證此類資訊所反映的預期將被證明是正確的。本新聞稿中的前瞻性資訊是截至本新聞稿發佈之日的前瞻性資訊，除適用的證券法規要求外，公司沒有義務更新或修改此類資訊以反映新的事件或情況。
The securities of the Company have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This release is issued for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
本公司的證券尚未根據1933年修訂的《美國證券法》進行登記，在沒有登記或獲得適用的豁免登記要求的情況下，不得在美國發售或出售。本新聞稿僅供參考，並不構成出售要約或徵求購買任何證券的要約，在任何司法管轄區內，也不得出售任何此類要約、徵求或出售將是非法的任何證券。
The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.
加拿大證券交易所(由CNSX Markets Inc.運營)既不批准也不反對本新聞稿的內容。
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE U.S.
不得分發給美國新聞通訊社或在美國境內傳播。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。